Management of Heart Failure in Primary Care and the use of Forxiga (dapagliflozin) – Speakers

Dr Jim Moore
President PCCS, GP, GPSI Cardiology in Gloucestershire

Dr Moore studied medicine in Edinburgh before moving to Gloucestershire to work as a GP principal. He has an interest in cardiology and cardiovascular disease, particularly those aspects that are relevant to Primary Care and contributes regularly to related educational events across the UK. He is President of the Primary Care Cardiovascular Society.

Dr Moore was involved in the development of the Primary Care based Gloucestershire Heart Failure service where he continues to work as a GPwSI.

He continues to represent Primary Care in the cardiovascular arena at both a local and national level. He has provided cardiovascular clinical support to local commissioning organisations for over ten years and remains actively involved in commissioning local cardiology services chairing the Circulatory Clinical Programme Group for Gloucestershire Clinical Commissioning Group (CCG). He was Clinical Lead for the community based West of England AHSN Stroke Prevention in AF project: Don’t wait to anticoagulate.

Dr Moore previously served on the board of the British Society for Heart Failure and was a member of the NICE Chronic Heart Failure Guideline committee (2018). He currently sits on the National Heart Failure Audit Steering group.

Dr Derek Connolly
PCCS Observer Committee Member, Consultant Interventional Cardiologist and Director of Research & Development, Birmingham City Hospital

Dr Derek Connolly is a Consultant Interventional Cardiologist and Honorary Senior Clinical Lecturer at Birmingham City Hospital, Birmingham UK.

He trained in Cambridge, London, Edinburgh and San Diego where he was a Carnegie Scholar. He has a first class degree in Pharmacology from the University of Edinburgh where he was the Brunton medallist and Keasbey Bursary holder. His PhD in molecular cardiology is from the University of Cambridge.

He is the Chief or Primary Investigator of multiple large trials in Cardiovascular medicine.

He developed one of the UKs first primary angioplasty programmes, and one of the UKs largest cardiac CT programmes.

AstraZeneca have provided financial sponsorship for this meeting and have had no involvement in the content or speaker selection.